Moors & Cabot Inc. Has $361,000 Stock Holdings in Sanofi (NASDAQ:SNY)

Moors & Cabot Inc. lessened its holdings in shares of Sanofi (NASDAQ:SNY) by 4.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 7,480 shares of the company’s stock after selling 355 shares during the quarter. Moors & Cabot Inc.’s holdings in Sanofi were worth $361,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Synergy Asset Management LLC bought a new position in shares of Sanofi during the 4th quarter valued at about $25,000. McClarren Financial Advisors Inc. raised its holdings in Sanofi by 952.6% during the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock worth $28,000 after buying an additional 543 shares during the period. Sunbelt Securities Inc. lifted its stake in Sanofi by 72.1% in the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after buying an additional 313 shares in the last quarter. Sierra Ocean LLC acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $44,000. Finally, Versant Capital Management Inc bought a new stake in shares of Sanofi during the fourth quarter worth $54,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

NASDAQ:SNY opened at $57.75 on Friday. The firm has a market capitalization of $146.56 billion, a price-to-earnings ratio of 23.19, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. Sanofi has a twelve month low of $45.22 and a twelve month high of $60.12. The stock’s 50 day moving average price is $53.65 and its two-hundred day moving average price is $52.83.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Equities research analysts expect that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on SNY. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Two investment analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $60.00.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.